文献速递肝病消化道肿瘤与早癌

乙型肝炎流行区肝与非肝恶性肿瘤患者免疫检查点抑制剂治疗期间的肝脏事件

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas.
PubMed 文献 · Aliment Pharmacol Ther · 2024-11-24

该研究回顾性分析了2014至2020年间在台北荣民总医院接受免疫检查点抑制剂(ICI)治疗的全部癌症患者数据,比较肝细胞癌(HCC)与非HCC恶性肿瘤患者肝脏不良事件的发生率和危险因素。结果显示HCC患者任何级别肝炎发作发生率显著高于非HCC患者(45.8% vs. 25.6%,p < 0.001),基线ALT > 40 U/L是肝脏不良事件的独立危险因素,核苷(酸)类似物(NUC)预防可最小化HBV再激活风险。

要点

  • HCC患者任何级别肝炎发作发生率显著高于非HCC患者(45.8% vs. 25.6%,p < 0.001)。
  • HCC和基线ALT > 40 U/L是≥3级肝炎发作的独立危险因素。
  • 283例HBsAg阳性患者中6例(2.1%)发生HBV再激活,HCC患者风险高于非HCC患者(4.4% vs. 0.6%)。

核心结论

  • 在ICI治疗下,HCC患者肝炎发作事件风险高于非HCC患者。
  • 基线ALT水平异常是肝脏不良事件的危险因素。
  • NUC预防可以最小化HBV再激活的风险。

研究设计与样本

  • 回顾性分析了2014年至2020年在台北荣民总医院接受ICI治疗的所有癌症患者数据。
  • 共1283例癌症患者纳入分析,其中190例HCC患者和1093例非HCC恶性肿瘤患者,283例(22.1%)为HBsAg阳性。
  • 通过Cox比例风险回归模型分析肝脏不良事件(包括肝炎发作、免疫相关肝炎和HBV再激活)的发生率和危险因素。

主要发现

  • HCC患者任何级别肝炎发作发生率显著高于非HCC患者(45.8% vs. 25.6%,p < 0.001)。
  • HCC和基线ALT > 40 U/L是≥3级肝炎发作事件的独立危险因素。
  • HCC患者与非HCC患者之间免疫相关肝炎风险无差异。
  • ALT > 40 U/L是免疫相关肝炎的独立危险因素。
  • 283例HBsAg阳性患者中6例(2.1%)发生HBV再激活,HCC患者风险高于非HCC患者(4.4% vs. 0.6%),未识别出HBV再激活的特异性危险因素,本研究中接受NUC预防的患者无一发生HBV再激活。

关键数值与推荐

  • HCC患者任何级别肝炎发作发生率为45.8%,非HCC患者为25.6%(p < 0.001)。
  • HBsAg阳性患者中HBV再激活发生率为2.1%(6/283),HCC患者为4.4%,非HCC患者为0.6%。
  • 基线ALT > 40 U/L被确定为肝脏不良事件的独立危险因素。

临床怎么用

  • 原文结论指出NUC预防可以最小化HBV再激活的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Notable advances have been made in immune checkpoint inhibitors (ICIs) for cancer treatment. However, the adverse effects of ICIs, especially hepatotoxicity, remain a challenging problem. Whether patients in hepatitis B virus (HBV)-endemic areas are prone to developing hepatic adverse events during ICI treatment warrants further exploration. METHODS: From 2014 to 2020, the data of all patients with cancer who received ICI treatment at Taipei Veterans General Hospital were retrospectively reviewed. The incidence of and risk factors for hepatic adverse events, including hepatitis flare, immune-related hepatitis (irHepatitis) and HBV reactivation (HBVr), were analysed through a Cox proportional hazard regression model. RESULTS: A total of 1283 patients with cancer (190 hepatocellular carcinoma [HCC] patients and 1093 patients with non-HCC malignancies) were eligible for analysis, of whom 283 (22.1%) were HBsAg-positive. The incidence of hepatitis flare events of any grade was significantly higher in HCC patients than in non-HCC patients (45.8% vs. 25.6%, p < 0.001). HCC and baseline alanine aminotransferase (ALT) > 40 U/L were independent risk factors for ≥ grade 3 hepatitis flare events. No difference was observed in irHepatitis risk between HCC patients and non-HCC patients. ALT > 40 U/L was an independent risk factor for irHepatitis. Among 283 HBsAg-positive patients, six patients (2.1%) experienced HBVr. HCC patients had a higher risk of HBVr than non-HCC patients (4.4% vs. 0.6%). No specific risk factor for HBVr could be identified. However, none of the patients under nucleos/tide analogue (NUC) prophylaxis experienced HBVr in this study. CONCLUSIONS: Under ICI treatment, HCC patients had a higher risk of hepatitis flare events than non-HCC patients. Abnormal baseline ALT levels are a risk factor for hepatic adverse events. NUC prophylaxis can minimise the risk of HBVr.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hung YP, Lee PC, Chang YH, et al. Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas. Aliment Pharmacol Ther. 2024. PMID: 39582238. doi:10.1111/apt.18403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。